Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?

BACKGROUND: Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown. METHODS: From August 1998 to June 2009, data from 1099 patients with CLM were collected prospectively. We retrospectively analyzed outcomes of patients who underwe...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Brouquet, Antoine (author)
مؤلفون آخرون: Overman, Micheal (author), Kopetz, Scott (author), Maru, Dipen (author), Loyer, Evelyne (author), Andreou, Andreas (author), Cooper, Amanda (author), Curley, Steven (author), Garrett, Christopher (author), Abdalla, Eddie (author), Vauthey, Jean-Nicolas (author)
التنسيق: article
منشور في: 2011
الوصول للمادة أونلاين:http://hdl.handle.net/10725/2628
http://dx.doi.org/10.1002/cncr.26036
http://onlinelibrary.wiley.com/doi/10.1002/cncr.26036/full
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513458985238528
author Brouquet, Antoine
author2 Overman, Micheal
Kopetz, Scott
Maru, Dipen
Loyer, Evelyne
Andreou, Andreas
Cooper, Amanda
Curley, Steven
Garrett, Christopher
Abdalla, Eddie
Vauthey, Jean-Nicolas
author2_role author
author
author
author
author
author
author
author
author
author
author_facet Brouquet, Antoine
Overman, Micheal
Kopetz, Scott
Maru, Dipen
Loyer, Evelyne
Andreou, Andreas
Cooper, Amanda
Curley, Steven
Garrett, Christopher
Abdalla, Eddie
Vauthey, Jean-Nicolas
author_role author
dc.creator.none.fl_str_mv Brouquet, Antoine
Overman, Micheal
Kopetz, Scott
Maru, Dipen
Loyer, Evelyne
Andreou, Andreas
Cooper, Amanda
Curley, Steven
Garrett, Christopher
Abdalla, Eddie
Vauthey, Jean-Nicolas
dc.date.none.fl_str_mv 2011
2015-11-19T09:54:29Z
2015-11-19T09:54:29Z
2017-05-23
dc.identifier.none.fl_str_mv 0008-543X
http://hdl.handle.net/10725/2628
http://dx.doi.org/10.1002/cncr.26036
Brouquet, A., Overman, M. J., Kopetz, S., Maru, D. M., Loyer, E. M., Andreou, A., ... & Vauthey, J. N. (2011). Is resection of colorectal liver metastases after a second‐line chemotherapy regimen justified?. Cancer, 117(19), 4484-4492.
http://onlinelibrary.wiley.com/doi/10.1002/cncr.26036/full
dc.language.none.fl_str_mv en
dc.relation.none.fl_str_mv Cancer
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.title.none.fl_str_mv Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description BACKGROUND: Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown. METHODS: From August 1998 to June 2009, data from 1099 patients with CLM were collected prospectively. We retrospectively analyzed outcomes of patients who underwent resection of CLM after second-line (2 or more) chemotherapy regimens. RESULTS: Sixty patients underwent resection of CLM after 2 or more chemotherapy regimens. Patients had advanced CLM (mean number of CLM ± standard deviation, 4 ± 3.5; mean maximum size of CLM, 5 ± 3.2 cm) and had received 17 ± 8 cycles of preoperative chemotherapy. In 54 (90%) patients, the switch from the first regimen to another regimen was motivated by tumor progression or suboptimal radiographic response. All patients received irinotecan or oxaliplatin, and the majority (42/60 [70%]) received a monoclonal antibody (bevacizumab or cetuximab) as part of the last preoperative regimen. Postoperative morbidity and mortality rates were 33% and 3%, respectively. At a median follow-up of 32 months, 1-year, 3-year, and 5-year overall survival rates were 83%, 41%, and 22%, respectively. Median chemotherapy-free survival after resection or completion of additional chemotherapy administered after resection was 9 months (95% confidence interval, 4-14 months). Synchronous (vs metachronous) CLM and minor (vs major) pathologic response were independently associated with worse survival. CONCLUSIONS: Resection of CLM after a second-line chemotherapy regimen was found to be safe and was associated with a modest hope for definitive cure. This approach represents a viable option in patients with advanced CLM. Cancer 2011;. © 2011 American Cancer Society.
eu_rights_str_mv openAccess
format article
id LAURepo_cc6e8025099e9d7ac2b529f6063bb8a8
identifier_str_mv 0008-543X
Brouquet, A., Overman, M. J., Kopetz, S., Maru, D. M., Loyer, E. M., Andreou, A., ... & Vauthey, J. N. (2011). Is resection of colorectal liver metastases after a second‐line chemotherapy regimen justified?. Cancer, 117(19), 4484-4492.
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/2628
publishDate 2011
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?Brouquet, AntoineOverman, MichealKopetz, ScottMaru, DipenLoyer, EvelyneAndreou, AndreasCooper, AmandaCurley, StevenGarrett, ChristopherAbdalla, EddieVauthey, Jean-NicolasBACKGROUND: Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown. METHODS: From August 1998 to June 2009, data from 1099 patients with CLM were collected prospectively. We retrospectively analyzed outcomes of patients who underwent resection of CLM after second-line (2 or more) chemotherapy regimens. RESULTS: Sixty patients underwent resection of CLM after 2 or more chemotherapy regimens. Patients had advanced CLM (mean number of CLM ± standard deviation, 4 ± 3.5; mean maximum size of CLM, 5 ± 3.2 cm) and had received 17 ± 8 cycles of preoperative chemotherapy. In 54 (90%) patients, the switch from the first regimen to another regimen was motivated by tumor progression or suboptimal radiographic response. All patients received irinotecan or oxaliplatin, and the majority (42/60 [70%]) received a monoclonal antibody (bevacizumab or cetuximab) as part of the last preoperative regimen. Postoperative morbidity and mortality rates were 33% and 3%, respectively. At a median follow-up of 32 months, 1-year, 3-year, and 5-year overall survival rates were 83%, 41%, and 22%, respectively. Median chemotherapy-free survival after resection or completion of additional chemotherapy administered after resection was 9 months (95% confidence interval, 4-14 months). Synchronous (vs metachronous) CLM and minor (vs major) pathologic response were independently associated with worse survival. CONCLUSIONS: Resection of CLM after a second-line chemotherapy regimen was found to be safe and was associated with a modest hope for definitive cure. This approach represents a viable option in patients with advanced CLM. Cancer 2011;. © 2011 American Cancer Society.PublishedN/A2015-11-19T09:54:29Z2015-11-19T09:54:29Z20112017-05-23Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0008-543Xhttp://hdl.handle.net/10725/2628http://dx.doi.org/10.1002/cncr.26036Brouquet, A., Overman, M. J., Kopetz, S., Maru, D. M., Loyer, E. M., Andreou, A., ... & Vauthey, J. N. (2011). Is resection of colorectal liver metastases after a second‐line chemotherapy regimen justified?. Cancer, 117(19), 4484-4492.http://onlinelibrary.wiley.com/doi/10.1002/cncr.26036/fullenCancerinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/26282021-03-19T09:59:49Z
spellingShingle Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet, Antoine
status_str publishedVersion
title Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
title_full Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
title_fullStr Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
title_full_unstemmed Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
title_short Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
title_sort Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
url http://hdl.handle.net/10725/2628
http://dx.doi.org/10.1002/cncr.26036
http://onlinelibrary.wiley.com/doi/10.1002/cncr.26036/full